即使siRNA被细胞内吞，也面临着从内吞体逃逸到细胞质中的难题，这是实现基因沉默效应的关键步骤。然而，对于许多非肝细胞而言，这一过程效率极低，限制了siRNA的效果。图3. Strategy for obtaining high-affinity chemically modified mannose–siRNA conjugate[2]除了上述问题之外，siRNA药物还需要具备良好的靶向性，即...
图3. Strategy for obtaining high-affinity chemically modified mannose–siRNA conjugate[2] 除了上述问题之外,siRNA药物还需要具备良好的靶向性,即能够在体内特异性地定位到病变部位,并在那里释放出足够的剂量以产生治疗效果。然而,当前的递送技术往往...
然而,对于许多非肝细胞而言,这一过程效率极低,限制了siRNA的效果。 图3. Strategy for obtaining high-affinity chemically modified mannose–siRNA conjugate[2] 除了上述问题之外,siRNA药物还需要具备良好的靶向性,即能够在体内特异性地定位到病变部位,并在那里释放出足够的剂量以产生治疗效果。然而,当前的递送技术往...
[33] Wang X X, Xiao X, Feng Y, et al. A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer[J]. Chem Sci, 2022, 13(18): 5345-5352. [34] 吕子阳 , 任欢欢 , 聂盛丹 , ...
5. What is small molecule siRNA conjugate? The small molecule siRNA conjugates is a compound wherein to a small interfering RNA (siRNA) is chemically attached a small molecule. The gene-silencing properties of siRNA are combined with the targeting or other functional properties of a small molecul...
A GalNAc-siRNA conjugate is a form of a GalNAC-siRNA in which the GalNAc molecule is linked to the siRNA molecule, usually at the 3′ end of the sense strand. This conjugate allows specific binding to hepatocytes because GalNAc attaches to asialoglycoprotein receptor on their cell surface. ...
SiRNA PHOSPHOLIPID CONJUGATEsiRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.Torchilin, Vladimir...
[11] Habtemariam, B. A. et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin. Pharmacol. Ther. 109, 372–382 (2021). ...
1.Henry Shion, Catalin E.Doneanu, ED Ha, Ying Qing Yu, Weibin Chen Analysis of Antibody siRNA Conjugate Using BioAccord System. Waters Application Note 720007212EN.2021. 2.P. Yogendrarajah, W. Verluytena, E. Dejaegere, L. Napoletano, J-P. Boona, M. Hellingsa, M. Gilar.(2021). 使...
Here, we report a dual-locked cyclopeptide–siRNA conjugate (DPRC) for tumor-specific siRNA delivery and gene silencing (Scheme 1). The DPRC consists of a PD-L1 (programmed cell death ligand 1)-targeting cyclopeptide, a Bcl-2 (B-cell lymphoma-2)-targeting siRNA (siBcl-2), and a glutath...